))
Huawei gets Its Way, Sarepta $SRPT Becomes The Leader
Manage episode 348584101 series 3183535
İçerik Behind The Bid tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Behind The Bid veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
Check out BehindTheBid.com, where you can get all of your premarket breakfast! https://www.behindthebid.com/posts/premarket-breakfast-for-monday-july-1st
Show notes:
Show notes July 1st, 2019:
Market closed July 4th and early day July 3rd (market closes at 1pm ET)
SPY Gap up on cooperative tone coming from US/China. Pres Trump and Pres Xi met on the sidelines of the G-20 Summit in Japan.
Trump ease restrictions to Huawei
Huawei is excited, tweets from official account.
Huawei can buy from US companies as long as not national security concern
Sarepta. Pfizer reported results for its drug for DMD (Duchenne muscular dystrophy, a legal muscle wasting disease that affects 12k american boys) at the PPMD Conference (Parent Project Muscular Dystrophy). Pfizer 6 patent study, after receiving gene-therapy 2 patents experienced side effects that ended them up in the hospital.
Safety concerns raised at PPMD conference. Sarepta went from being a front-runner to basically a standalone in DMD.
Solid Biosciences $SLDB also popped but their study was already a fail.
50 bölüm
Paylaş
